ARTICLE | Clinical News
GWP42006: Phase I started
September 23, 2013 7:00 AM UTC
GW Pharma began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single and multiple ascending-doses of 25, 75, 200 and 400 mg oral GWP42006 in about 55 healthy volunteers. The trial...